HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

S18-000003

A novel RORgamma t inhibitor

Also Known As:

N-(2,4-difluorophenyl)-2-(4-((2-(4-ethylsulfonylphenyl)acetyl)amino)-2-fluorophenyl)-2-methylpropanamide

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Sulfur Compounds: 278
  - Sulfones: 534
    - S18-000003: 1

Experts

1.	Furue, Yoko: 1 article (03/2019)
2.	Imura, Chihiro: 1 article (03/2019)
3.	Katayama, Kazufumi: 1 article (03/2019)
4.	Okuno, Takayuki: 1 article (03/2019)
5.	Sasaki, Yoshikazu: 1 article (03/2019)
6.	Shichijo, Michitaka: 1 article (03/2019)
7.	Shimizu, Masaya: 1 article (03/2019)
8.	Tai, Nobuyuki: 1 article (03/2019)
9.	Tsujii, Kenichiro: 1 article (03/2019)
10.	Ueyama, Azumi: 1 article (03/2019)

Related Diseases

1.	Psoriasis (Pustulosis Palmaris et Plantaris) 03/01/2019 - "In the skin, S18-000003 suppressed all subsets of IL-17-producing cells that we previously identified in this psoriasis model: Th17 cells, Tc17 cells, dermal γδ T cells, TCR- cells that probably included innate lymphoid cells, and CD4-CD8- double-negative αβ T cells. " 03/01/2019 - "We investigated whether topical administration of our novel RORγt inhibitor, S18-000003 has therapeutic potential for psoriasis with low risk of thymic aberrations. " 03/01/2019 - "We evaluated the effect of topical S18-000003 on psoriasis-like skin inflammation and influence on the thymus in a 12-O-tetradecanoylphorbol-13-acetate-induced K14.Stat3C mouse psoriasis model. "
2.	Inflammation (Inflammations) 03/01/2019 - "We evaluated the effect of topical S18-000003 on psoriasis-like skin inflammation and influence on the thymus in a 12-O-tetradecanoylphorbol-13-acetate-induced K14.Stat3C mouse psoriasis model. " 03/01/2019 - "S18-000003 markedly inhibited the development of psoriatic skin inflammation via suppression of the IL-17 pathway. "

Related Drugs and Biologics

1.	Interleukin-17 (Interleukin 17)

Related Therapies and Procedures

1.	Topical Administration